These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34214842)

  • 21. Identification of pyrrolo[2,3-d]pyrimidines as potent HCK and FLT3-ITD dual inhibitors.
    Koda Y; Kikuzato K; Mikuni J; Tanaka A; Yuki H; Honma T; Tomabechi Y; Kukimoto-Niino M; Shirouzu M; Shirai F; Koyama H
    Bioorg Med Chem Lett; 2017 Nov; 27(22):4994-4998. PubMed ID: 29037944
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potent and selective EGFR inhibitors based on 5-aryl-7H-pyrrolopyrimidin-4-amines.
    Reiersølmoen AC; Aarhus TI; Eckelt S; Nørsett KG; Sundby E; Hoff BH
    Bioorg Chem; 2019 Jul; 88():102918. PubMed ID: 30999245
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design, synthesis and biological evaluation of 7H-pyrrolo[2,3-d]pyrimidin-4-amine derivatives as selective Btk inhibitors with improved pharmacokinetic properties for the treatment of rheumatoid arthritis.
    He L; Pei H; Zhang C; Shao M; Li D; Tang M; Wang T; Chen X; Xiang M; Chen L
    Eur J Med Chem; 2018 Feb; 145():96-112. PubMed ID: 29324347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N2-Trimethylacetyl substituted and unsubstituted-N4-phenylsubstituted-6-(2-pyridin-2-ylethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines: design, cellular receptor tyrosine kinase inhibitory activities and in vivo evaluation as antiangiogenic, antimetastatic and antitumor agents.
    Gangjee A; Namjoshi OA; Yu J; Ihnat MA; Thorpe JE; Bailey-Downs LC
    Bioorg Med Chem; 2013 Mar; 21(5):1312-23. PubMed ID: 23375090
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress in the Development of Small Molecular Inhibitors of Focal Adhesion Kinase (FAK).
    Lu Y; Sun H
    J Med Chem; 2020 Dec; 63(23):14382-14403. PubMed ID: 33058670
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Design, synthesis and evaluation of pyrrolo[2,3-d]pyrimidine-phenylamide hybrids as potent Janus kinase 2 inhibitors.
    Wang T; Liu X; Hao M; Qiao J; Ju C; Xue L; Zhang C
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2936-2941. PubMed ID: 27130359
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design, synthesis, biological evaluation and molecular docking study of novel thieno[3,2-d]pyrimidine derivatives as potent FAK inhibitors.
    Wang R; Yu S; Zhao X; Chen Y; Yang B; Wu T; Hao C; Zhao D; Cheng M
    Eur J Med Chem; 2020 Feb; 188():112024. PubMed ID: 31923858
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Discovery of 7H-pyrrolo[2,3-d]pyrimidine derivatives as selective covalent irreversible inhibitors of interleukin-2-inducible T-cell kinase (Itk).
    Tang G; Liu L; Wang X; Pan Z
    Eur J Med Chem; 2019 Jul; 173():167-183. PubMed ID: 30999237
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synthesis and optimization of substituted furo[2,3-d]-pyrimidin-4-amines and 7H-pyrrolo[2,3-d]pyrimidin-4-amines as ACK1 inhibitors.
    Jiao X; Kopecky DJ; Liu J; Liu J; Jaen JC; Cardozo MG; Sharma R; Walker N; Wesche H; Li S; Farrelly E; Xiao SH; Wang Z; Kayser F
    Bioorg Med Chem Lett; 2012 Oct; 22(19):6212-7. PubMed ID: 22929232
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
    Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
    Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of new pyrrolo[2,3-d]pyrimidines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, biological evaluation and molecular modeling.
    Adel M; Serya RAT; Lasheen DS; Abouzid KAM
    Bioorg Chem; 2018 Dec; 81():612-629. PubMed ID: 30248512
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel 5,6-disubstituted pyrrolo[2,3-d]pyrimidine derivatives as broad spectrum antiproliferative agents: Synthesis, cell based assays, kinase profile and molecular docking study.
    Lee JH; El-Damasy AK; Seo SH; Gadhe CG; Pae AN; Jeong N; Hong SS; Keum G
    Bioorg Med Chem; 2018 Nov; 26(21):5596-5611. PubMed ID: 30385226
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of focal adhesion kinase by PF-562,271 inhibits the growth and metastasis of pancreatic cancer concomitant with altering the tumor microenvironment.
    Stokes JB; Adair SJ; Slack-Davis JK; Walters DM; Tilghman RW; Hershey ED; Lowrey B; Thomas KS; Bouton AH; Hwang RF; Stelow EB; Parsons JT; Bauer TW
    Mol Cancer Ther; 2011 Nov; 10(11):2135-45. PubMed ID: 21903606
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pyrrolo[2,3-d]pyrimidine derivatives as inhibitors of RET: Design, synthesis and biological evaluation.
    Lakkaniga NR; Gunaganti N; Zhang L; Belachew B; Frett B; Leung YK; Li HY
    Eur J Med Chem; 2020 Nov; 206():112691. PubMed ID: 32823007
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of focal adhesion kinase catalytic activity on the proliferation and migration of squamous cell carcinoma cells.
    Serrels A; McLeod K; Canel M; Kinnaird A; Graham K; Frame MC; Brunton VG
    Int J Cancer; 2012 Jul; 131(2):287-97. PubMed ID: 21823119
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis, and docking studies of phenylpyrimidine-carboxamide derivatives bearing 1H-pyrrolo[2,3-b]pyridine moiety as c-Met inhibitors.
    Zhu W; Wang W; Xu S; Wang J; Tang Q; Wu C; Zhao Y; Zheng P
    Bioorg Med Chem; 2016 Apr; 24(8):1749-56. PubMed ID: 26964675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Synthesis and biological activity of N(4)-phenylsubstituted-6-(2,4-dichloro phenylmethyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamines as vascular endothelial growth factor receptor-2 inhibitors and antiangiogenic and antitumor agents.
    Gangjee A; Kurup S; Ihnat MA; Thorpe JE; Shenoy SS
    Bioorg Med Chem; 2010 May; 18(10):3575-87. PubMed ID: 20403700
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 3'3-Diindolylmethane inhibits migration, invasion and metastasis of hepatocellular carcinoma by suppressing FAK signaling.
    Li WX; Chen LP; Sun MY; Li JT; Liu HZ; Zhu W
    Oncotarget; 2015 Sep; 6(27):23776-92. PubMed ID: 26068982
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis, and biological evaluation of novel FAK scaffold inhibitors targeting the FAK-VEGFR3 protein-protein interaction.
    Gogate PN; Ethirajan M; Kurenova EV; Magis AT; Pandey RK; Cance WG
    Eur J Med Chem; 2014 Jun; 80():154-166. PubMed ID: 24780592
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A small molecule inhibitor, 1,2,4,5-benzenetetraamine tetrahydrochloride, targeting the y397 site of focal adhesion kinase decreases tumor growth.
    Golubovskaya VM; Nyberg C; Zheng M; Kweh F; Magis A; Ostrov D; Cance WG
    J Med Chem; 2008 Dec; 51(23):7405-16. PubMed ID: 18989950
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.